Antibody-drug conjugates (ADCs) clinical trials
A class of medicines: the studies that test any of its 23 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Immunoconjugates.
Get an email when these change. Save the antibody-drug conjugates (adcs) studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
- Cofetuzumab pelidotin
- 2
- BAY 2315497
- 1
- CX-2029
- 1
- LY3076226
- 1
- MEDI4276
- 1
Studies by the year they started
1,098 studies that test it; most in 2026 (134); 17 more planned to start later
| Year | Studies |
|---|---|
| 2000 | 5 |
| 2001 | 4 |
| 2002 | 6 |
| 2003 | 5 |
| 2004 | 8 |
| 2005 | 3 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 9 |
| 2009 | 15 |
| 2010 | 9 |
| 2011 | 16 |
| 2012 | 23 |
| 2013 | 30 |
| 2014 | 26 |
| 2015 | 27 |
| 2016 | 28 |
| 2017 | 38 |
| 2018 | 52 |
| 2019 | 51 |
| 2020 | 57 |
| 2021 | 82 |
| 2022 | 88 |
| 2023 | 118 |
| 2024 | 120 |
| 2025 | 131 |
| 2026 | 134 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 418 · Other 698
Merck Sharp & Dohme LLC (47) · AstraZeneca (41) · Daiichi Sankyo (40) · M.D. Anderson Cancer Center (38) · Hoffmann-La Roche (37) · National Cancer Institute (NCI) (29) · RemeGen Co., Ltd. (29) · Seagen Inc. (26)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 1,116
- A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on ImmunotherapyNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07939204Written as Sacituzumab Tirumotecan
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06686394Written as Patritumab deruxtecan
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingPhase 3AstraZenecaNCT06989112Written as Trastuzumab deruxtecan
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07829783Written as Sac-TMT
- Sac-TMT in Vaginal and Vulvar CancersNot yet recruitingPhase 2Latin American Cooperative Oncology GroupNCT07804966Written as Sacituzumab Tirumotecan (sac-TMT)
- A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsNot yet recruitingPhase 2Centre Leon BerardNCT07936422Written as Trastuzumab Deruxtecan for Injection (T-DXd)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06469944Written as Sacituzumab Tirumotecan (sac-TMT)
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780111Written as I-DXd
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06780098Written as I-DXD
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07069595Written as Datopotamab deruxtecan
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)RecruitingPhase 1Sunil G. IyerNCT07936266Written as Inotuzumab ozogamicin
- A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy(NCCH2407/MK014)Not yet recruitingPhase 2National Cancer Center, JapanNCT07913568Written as Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab
- MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerNot yet recruitingPhase 2Tongji HospitalNCT07934121Written as Mirvetuximab Soravtansine
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Sacituzumab Govitecan
- Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorRecruitingPhase 2National Cancer Institute (NCI)NCT04616560Written as Trastuzumab Deruxtecan
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingPhase 1National Cancer Institute (NCI)NCT05372614Written as Trastuzumab Deruxtecan
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Patritumab deruxtecan
- A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaRecruitingPhase 1M.D. Anderson Cancer CenterNCT05055063Written as Belantamab mafodotin
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04585958Written as Trastuzumab Deruxtecan
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Brentuximab Vedotin
See all 1,116 studies that test one of the antibody-drug conjugates (adcs) →
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting5
- Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)Nov 9, 2026NCT07573436
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)Nov 6, 2026NCT07829783
- Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyOct 29, 2026NCT06680596
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaOct 26, 2026NCT04822337
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)Oct 26, 2026NCT07476729
Results posted4
- Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple MyelomaNov 9, 2026NCT04091126
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaOct 29, 2026NCT03712202
- Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular LymphomaOct 28, 2026NCT05410418
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLOct 21, 2026NCT04404283
Stopped2
- Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaSuspendedNov 16, 2026NCT05600686
- A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung CancerWithdrawnOct 20, 2026NCT07428044
Newly registered16
- A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on ImmunotherapyNov 16, 2026NCT07939204
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)Nov 13, 2026NCT07936266
- A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsNov 13, 2026NCT07936422
- MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerNov 12, 2026NCT07934121
- Sac-TMT in Salivary Gland CancersNov 10, 2026NCT07928193
Show 11 moreShow fewer
- Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate CancerNov 9, 2026NCT07925268
- Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLNov 6, 2026NCT07921550
- A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy(NCCH2407/MK014)Nov 3, 2026NCT07913568
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Nov 2, 2026NCT07908524
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective StudyNov 2, 2026NCT07908888
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerNov 2, 2026NCT07908979
- Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialNov 2, 2026NCT07910435
- Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum ChemotherapyOct 30, 2026NCT07907861
- Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Oct 29, 2026NCT07905313
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]Oct 22, 2026NCT07890714
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasOct 20, 2026NCT07883135
Codes
What other systems call Antibody-drug conjugates (ADCs) · ClinicalTrials.gg INT008651
- MeSH (NLM) D018796ImmunoconjugatesOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D018796 | Immunoconjugates | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.